Cargando…
How and when to refer patients for oncogenetic counseling in the era of PARP inhibitors
Poly(ADP-ribose)polymerase (PARP) inhibitors are targeted therapy for cancers with homologous repair deficiency (HRD). They were first approved for ovarian cancer and have changed current treatment strategies. They have also demonstrated efficacy in HER2-negative metastatic breast cancer and advance...
Autores principales: | Neviere, Zoé, De La Motte Rouge, Thibault, Floquet, Anne, Johnson, Alison, Berthet, Pascaline, Joly, Florence |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052467/ https://www.ncbi.nlm.nih.gov/pubmed/32165926 http://dx.doi.org/10.1177/1758835919897530 |
Ejemplares similares
-
Permanence of the information given during oncogenetic counseling to persons at familial risk of breast/ovarian and/or colon cancer
por: Kwiatkowski, Fabrice, et al.
Publicado: (2012) -
Oncogenetic landscape of lymphomagenesis in coeliac disease
por: Cording, Sascha, et al.
Publicado: (2022) -
Oncogenetics service and the Brazilian public health system: the
experience of a reference Cancer Hospital
por: Palmero, Edenir I., et al.
Publicado: (2016) -
The Use of a Diagnostic Database in Clinical Oncogenetics
por: Sijmons, Rolf H, et al.
Publicado: (2003) -
The withdrawal from oncogenetic counselling and testing for hereditary and familial breast and ovarian cancer. A descriptive study of an Italian sample
por: Caruso, Anita, et al.
Publicado: (2008)